The Federal Court has dismissed Elanco’s application for judicial review of the Minister of Health’s refusal to list Canadian Patent No. 2,812,704 on the Patent Register in respect of IMPRESTOR (pegbovigrastim): Elanco v Canada (Attorney General), 2019 FC 5. The Minister assigned a filing date for Elanco’s New Drug Submission (NDS) as the date the Veterinary Drugs Directorate determined the submission to be administratively complete, rather than the date on which all substantive components of the submission were provided for evaluation. All substantive components had not initially been submitted as Health Canada had agreed that Elanco could participate in a phased submission process, aligned with the timeline for submission of data to the United States Food and Drug Administration to enable simultaneous reviews. The Judge found that the Minister’s determination of the filing date was reasonable. Since Elanco filed its patent application after the NDS filing date, the patent did not meet the timing requirements for listing eligibility under subsection 4(6) of the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations). Elanco did not appeal.
Related Publications & Articles
-
Supreme Court of Canada dismisses Apotex and Pharmascience’s applications for leave to appeal paliperidone inducing infringement decisions
On June 27, 2024, the Supreme Court of Canada dismissed Apotex and Pharmascience’s applications for leave to appeal (Docket Nos. 41162 and 41164).Read More -
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More